The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...
Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile. Freimer was an author on 5 abstracts presented at the ...
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
People with myasthenia gravis may need to use many different medicines to manage their symptoms. In recent years, a new group of medicines called complement inhibitors have been approved to treat this ...
Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback